Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route
NCT ID: NCT02449174
Last Updated: 2019-03-25
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
69 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-03-17
Study Completion Date
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of the study is to investigate the safety of a frozen or lyophilized inoculum administered, respectively, by retention enema or capsules in patients with recurrent C. difficile associated diarrhea (RCDAD).
This is a single center, randomized, parallel assignment, open label safety study conducted in subjects with RCDAD. Fifty subjects will be enrolled in the study and randomized at 1:1 ratio to receive frozen filtered intestinal bacteria via retention enema or lyophilized donor intestinal bacteria. All subjects will be followed for a total of 3 years after study completion.
Donors will be enrolled and screened at the laboratory in the Center for Infectious Diseases at University of Texas School of Public Health (UT-SPH). The donors will come from a variety of places, including the UT-SPH. At least 20 donors will be screened to recruit at least 15 qualified donors.
Recipients may self-refer but must have a physician who agrees to accept care of the patient following fecal microbiota transplantation (FMT). Subjects consenting to treatment at Baylor St. Luke's Medical Center (BSLMC) and the UT-SPH must be willing to self-pay for the FMT in the amount of $1,500. There will be no insurance accepted. Subjects undergoing retention enema will be treated as outpatients at either at BSLMC, Kelsey-Seybold Clinic, or at the Memorial Hermann in the Texas Medical Center. All subjects taking capsules with lyophilized intestinal bacteria will be seen at UT-SPH. Once the procedure is completed, the recipient's care will be returned to their physician. At least 75 recipients will be screened to recruit 50 qualified recipients.
The primary endpoint is to evaluate the safety of FMT by rectal or oral routes with secondary endpoint related to efficacy prevention of RCDAD. In order to monitor any health effects for safety, participants will be contacted pre- and 7, 14, 30 days, then monthly basis for the first 90 days after FMT and quarterly till 3 years after FMT. The following procedures will be completed: review recipient diary with the recipient to ensure that the following information is recorded correctly and a fresh stool sample will be collected from recipient, tested for C. difficile toxins and an aliquot (2mL) stored at -80C for microbiome analysis. Recipients will be contacted by phone for their diarrhea status on monthly basis till 90 days after FMT, then on quarterly basis till 3 years after FMT.
This is a single center, randomized, parallel assignment, open label safety study conducted in subjects with RCDAD. Fifty subjects will be enrolled in the study and randomized at 1:1 ratio to receive frozen filtered intestinal bacteria via retention enema or lyophilized donor intestinal bacteria. All subjects will be followed for a total of 3 years after study completion.
Donors will be enrolled and screened at the laboratory in the Center for Infectious Diseases at University of Texas School of Public Health (UT-SPH). The donors will come from a variety of places, including the UT-SPH. At least 20 donors will be screened to recruit at least 15 qualified donors.
Recipients may self-refer but must have a physician who agrees to accept care of the patient following fecal microbiota transplantation (FMT). Subjects consenting to treatment at Baylor St. Luke's Medical Center (BSLMC) and the UT-SPH must be willing to self-pay for the FMT in the amount of $1,500. There will be no insurance accepted. Subjects undergoing retention enema will be treated as outpatients at either at BSLMC, Kelsey-Seybold Clinic, or at the Memorial Hermann in the Texas Medical Center. All subjects taking capsules with lyophilized intestinal bacteria will be seen at UT-SPH. Once the procedure is completed, the recipient's care will be returned to their physician. At least 75 recipients will be screened to recruit 50 qualified recipients.
The primary endpoint is to evaluate the safety of FMT by rectal or oral routes with secondary endpoint related to efficacy prevention of RCDAD. In order to monitor any health effects for safety, participants will be contacted pre- and 7, 14, 30 days, then monthly basis for the first 90 days after FMT and quarterly till 3 years after FMT. The following procedures will be completed: review recipient diary with the recipient to ensure that the following information is recorded correctly and a fresh stool sample will be collected from recipient, tested for C. difficile toxins and an aliquot (2mL) stored at -80C for microbiome analysis. Recipients will be contacted by phone for their diarrhea status on monthly basis till 90 days after FMT, then on quarterly basis till 3 years after FMT.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea
NCT02318992
Recurrent C. Difficile Associated Diarrhea
COMPLETED
PHASE1/PHASE2
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
NCT03353506
Enterocolitis
Recurrent Clostridium Difficile Infection
COMPLETED
PHASE2
Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)
NCT03548051
Clostridial Infection
Dysbiosis
Probiotic Therapy
TERMINATED
PHASE1/PHASE2
Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea
NCT01868373
Active C. Difficile Colitis
ENROLLING_BY_INVITATION
PHASE1
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
NCT03806803
Clostridia Difficile Colitis
Clostridium Difficile Diarrhea
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical improvement is monitored by telephone/email and or E-mail up to 3 years after FMT. Minor clinical management of the subject with over the counter medication (e.g. loperamide, acetaminophen and Saccharomyces boulardii \[probiotic\]) will be performed in the case of mild diarrhea and abdominal pain.
All subjects will be followed up by phone the day after FMT to assess health status during week one. Study subjects will be monitored on approximately days 7, 14 and 30, monthly for the first 3 month and quarterly for 3 years after FMT, at which time the recipient diary will be reviewed with the recipient to review any adverse experience or medication taken since the medical history obtained at FMT.
Investigators should determine if any adverse experience or medication need to be further studied. Donor will be contacted and tested if it is necessary. All actions will be recorded on with medical condition, dates of adverse experience and medication taken, indication for new medication taken, and total daily dose.
Recipients should be instructed at FMT to contact the Investigator if they have any questions regarding adverse experience or the appropriateness of a medication after FMT.
The following definitions of terms are guided by the International Conference of Harmonization and US Code of Federal Regulations (21 CFR 312.32).
An adverse experience is any unfavorable or unintended sign, symptom, of disease temporally associated with FMT procedure, whether or not considered related to the procedure, including, but not limited to:
* Any symptom not previously reported by the recipients (Recent Medical History)
* An exacerbation of a pre-existing illness, increases in the frequency and/or severity of the signs or symptoms of CDAD (defined as positive C. difficile toxin test and enteric symptoms)
* A significant increase in frequency or intensity of a pre-existing episodic event or condition
* A condition first detected or diagnosed after study drug administration even through the condition may have been present before the procedure Details of all adverse experiences that occur after FMT through approximately day 90 visit will be collected as indicated above. Then the subject will be followed on quarterly basis for 3 years about their CDAD and other medical concerns
Serious adverse experience is any adverse experience that:
* Results in death
* Is life threatening (at immediate risk of death from the procedure as it occurred)
* Requires inpatient hospitalization (overnight stay) or prolongs a current hospitalization
* Causes a persistent or significant disability/incapacity
* Medical important (any event that requires medical or surgical intervention to prevent one of the outcomes listed above) The investigator will exercise medical and scientific judgment when deciding whether expeditious reporting is appropriate in other situations not strictly meeting the listed criteria above. The investigators will meet/discuss with experts in the field if there is a question of whether the adverse experience would be considered serious.
Severity - The adverse experience will be documented on the appropriate page in the Patient Diary according to the following descriptors:
* Mild: associated with no limitation of usual activities or only slight discomfort
* Moderate: associated with limitation of usual activities or significant discomfort
* Severe: associated with inability to carry out usual activities or very marked discomfort
Relationship - the relationship of adverse experience to FMT will be assigned by the Investigator according to the following definitions:
* Probable: a reaction that follows a reasonable temporal sequence from the procedure that follows a known or expected response pattern to the suspected procedure and that could not be reasonably explained by the known characteristics of that patient's clinical state
* Possible: a reaction that follows a reasonable temporal sequence from the procedure that follows a known or expected response pattern to the procedure but could readily have been produced by a number of other factors
* Unlikely: a reaction that does not follow a reasonable temporal sequence from the procedure but for which causality from FMT cannot be ruled out.
* Not related: a reaction for which sufficient data exist to indicate that the etiology is unrelated to the procedure Pre-existing signs and symptoms and medical conditions Medical conditions that are present at or before the procedure that manifest with the same severity or frequency will not be recorded as adverse experience. Similarly, signs or symptoms related to a pre-existing disease will not be recorded as adverse experience unless there is an increase in the severity or frequency of the signs or symptoms. These pre-existing conditions, signs, or symptoms will be recorded on the Recent Medical History Form.
Progression of underlying conditions as an adverse experience
If the progression of the underlying condition might be reasonably anticipated given the nature and severity of the underlying condition, then the progression of the underlying condition per se will not constitute an adverse experience. However, if the progression of the underlying condition is fatal, then the progression of the underlying condition should be reported as an adverse experience.
Recording and documenting adverse experience
The Investigator must completely and promptly record each new adverse experience and serious adverse experience, even if the relationship of adverse experience to the procedure is assessed by the Investigator to be "unlikely" or "not related". In addition, the investigator must document and follow serious adverse experiences that occur from the procedure through 3 years after the FMT. The Investigator should attempt, if possible, to establish a diagnosis based on the presenting signs and symptoms. If an adverse experience meets the definition of a serious adverse experience then the Investigator must also complete the serious adverse experience, and also send any supporting source documents directly to the University of Texas Health Science Center IRB as soon as the event is discovered. At each visit, after the patient has had an opportunity to mention any problems spontaneously, the Investigator (or designee) will inquire about adverse experience by asking the standard questions listed in, such as:
* Have you had any medical problems since your last visit?
* Have any medical problems present at your last visit changed, i.e., stopped, worsened, or improved?
* Have you taken any new medicines, other than study drug, since your last visit? Any spontaneous adverse experience information provided by the patient will be reported. If an adverse experience has not resolved at the time of the Final Visit, the Investigator should evaluate the status of the adverse experience at the Follow-Up telephone/email contact (day 60) and update to reflect the status of the adverse experience (e.g. ongoing or resolved).
Investigator reporting of serious adverse experience All serious adverse experience must be reported to the University of Texas Health Science IRB using the serious adverse experience facsimile or email or by telephone/email as soon as the serious adverse experience is discovered, and within 24 hours after the Investigator recognizes or classifies the event as a serious adverse experience. A brief description of the event must be provided at the time of the initial serious adverse experience report. The initial serious adverse experience report should be followed up by additional information using the serious adverse experience within 48 hours. The reports should identify the patient by their unique patient number instead of names. The completed serious adverse experience Form will be used by the investigators in regulatory filings. The investigator is responsible for continuing to report to the University of Texas Health Science IRB any new or relevant follow-up information obtained concerning the serious adverse experience. The results of any additional assessments conducted must be also reported to the University of Texas Health Science IRB.
Notification of post-study serious adverse experience Investigators are not obligated to actively seek follow-up information for patients with adverse experience after the conclusion of the study (i.e., \> 3 years after the FMT procedure). However, if the investigator becomes aware of an adverse experience that occurs after the patient completes and the adverse experience is considered by the Investigator to be at least possibly related to study procedure, the investigator must notify the University of Texas Health Science Center IRB.
All subjects will be followed up by phone the day after FMT to assess health status during week one. Study subjects will be monitored on approximately days 7, 14 and 30, monthly for the first 3 month and quarterly for 3 years after FMT, at which time the recipient diary will be reviewed with the recipient to review any adverse experience or medication taken since the medical history obtained at FMT.
Investigators should determine if any adverse experience or medication need to be further studied. Donor will be contacted and tested if it is necessary. All actions will be recorded on with medical condition, dates of adverse experience and medication taken, indication for new medication taken, and total daily dose.
Recipients should be instructed at FMT to contact the Investigator if they have any questions regarding adverse experience or the appropriateness of a medication after FMT.
The following definitions of terms are guided by the International Conference of Harmonization and US Code of Federal Regulations (21 CFR 312.32).
An adverse experience is any unfavorable or unintended sign, symptom, of disease temporally associated with FMT procedure, whether or not considered related to the procedure, including, but not limited to:
* Any symptom not previously reported by the recipients (Recent Medical History)
* An exacerbation of a pre-existing illness, increases in the frequency and/or severity of the signs or symptoms of CDAD (defined as positive C. difficile toxin test and enteric symptoms)
* A significant increase in frequency or intensity of a pre-existing episodic event or condition
* A condition first detected or diagnosed after study drug administration even through the condition may have been present before the procedure Details of all adverse experiences that occur after FMT through approximately day 90 visit will be collected as indicated above. Then the subject will be followed on quarterly basis for 3 years about their CDAD and other medical concerns
Serious adverse experience is any adverse experience that:
* Results in death
* Is life threatening (at immediate risk of death from the procedure as it occurred)
* Requires inpatient hospitalization (overnight stay) or prolongs a current hospitalization
* Causes a persistent or significant disability/incapacity
* Medical important (any event that requires medical or surgical intervention to prevent one of the outcomes listed above) The investigator will exercise medical and scientific judgment when deciding whether expeditious reporting is appropriate in other situations not strictly meeting the listed criteria above. The investigators will meet/discuss with experts in the field if there is a question of whether the adverse experience would be considered serious.
Severity - The adverse experience will be documented on the appropriate page in the Patient Diary according to the following descriptors:
* Mild: associated with no limitation of usual activities or only slight discomfort
* Moderate: associated with limitation of usual activities or significant discomfort
* Severe: associated with inability to carry out usual activities or very marked discomfort
Relationship - the relationship of adverse experience to FMT will be assigned by the Investigator according to the following definitions:
* Probable: a reaction that follows a reasonable temporal sequence from the procedure that follows a known or expected response pattern to the suspected procedure and that could not be reasonably explained by the known characteristics of that patient's clinical state
* Possible: a reaction that follows a reasonable temporal sequence from the procedure that follows a known or expected response pattern to the procedure but could readily have been produced by a number of other factors
* Unlikely: a reaction that does not follow a reasonable temporal sequence from the procedure but for which causality from FMT cannot be ruled out.
* Not related: a reaction for which sufficient data exist to indicate that the etiology is unrelated to the procedure Pre-existing signs and symptoms and medical conditions Medical conditions that are present at or before the procedure that manifest with the same severity or frequency will not be recorded as adverse experience. Similarly, signs or symptoms related to a pre-existing disease will not be recorded as adverse experience unless there is an increase in the severity or frequency of the signs or symptoms. These pre-existing conditions, signs, or symptoms will be recorded on the Recent Medical History Form.
Progression of underlying conditions as an adverse experience
If the progression of the underlying condition might be reasonably anticipated given the nature and severity of the underlying condition, then the progression of the underlying condition per se will not constitute an adverse experience. However, if the progression of the underlying condition is fatal, then the progression of the underlying condition should be reported as an adverse experience.
Recording and documenting adverse experience
The Investigator must completely and promptly record each new adverse experience and serious adverse experience, even if the relationship of adverse experience to the procedure is assessed by the Investigator to be "unlikely" or "not related". In addition, the investigator must document and follow serious adverse experiences that occur from the procedure through 3 years after the FMT. The Investigator should attempt, if possible, to establish a diagnosis based on the presenting signs and symptoms. If an adverse experience meets the definition of a serious adverse experience then the Investigator must also complete the serious adverse experience, and also send any supporting source documents directly to the University of Texas Health Science Center IRB as soon as the event is discovered. At each visit, after the patient has had an opportunity to mention any problems spontaneously, the Investigator (or designee) will inquire about adverse experience by asking the standard questions listed in, such as:
* Have you had any medical problems since your last visit?
* Have any medical problems present at your last visit changed, i.e., stopped, worsened, or improved?
* Have you taken any new medicines, other than study drug, since your last visit? Any spontaneous adverse experience information provided by the patient will be reported. If an adverse experience has not resolved at the time of the Final Visit, the Investigator should evaluate the status of the adverse experience at the Follow-Up telephone/email contact (day 60) and update to reflect the status of the adverse experience (e.g. ongoing or resolved).
Investigator reporting of serious adverse experience All serious adverse experience must be reported to the University of Texas Health Science IRB using the serious adverse experience facsimile or email or by telephone/email as soon as the serious adverse experience is discovered, and within 24 hours after the Investigator recognizes or classifies the event as a serious adverse experience. A brief description of the event must be provided at the time of the initial serious adverse experience report. The initial serious adverse experience report should be followed up by additional information using the serious adverse experience within 48 hours. The reports should identify the patient by their unique patient number instead of names. The completed serious adverse experience Form will be used by the investigators in regulatory filings. The investigator is responsible for continuing to report to the University of Texas Health Science IRB any new or relevant follow-up information obtained concerning the serious adverse experience. The results of any additional assessments conducted must be also reported to the University of Texas Health Science IRB.
Notification of post-study serious adverse experience Investigators are not obligated to actively seek follow-up information for patients with adverse experience after the conclusion of the study (i.e., \> 3 years after the FMT procedure). However, if the investigator becomes aware of an adverse experience that occurs after the patient completes and the adverse experience is considered by the Investigator to be at least possibly related to study procedure, the investigator must notify the University of Texas Health Science Center IRB.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
C. Difficile
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Allocation: Randomized Endpoints: Safety, preliminary efficacy in preventing future bouts of CDAD and improvement in intestinal flora diversity Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
frozen intestinal bacteria from a healthy donor given by retention enema or lyophilized intestinal bacteria given orally in capsules for therapy in subjects with recurrent C. difficile associated diarrhea (RCDAD)
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Frozen Microbiota
Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
Group Type
ACTIVE_COMPARATOR
Frozen Microbiota
Intervention Type
BIOLOGICAL
Frozen Microbiota will be delivered via enema route.
Lyophilized Microbiota
Lyophilized Microbiota\_Donor stool (greater than 150 grams) was collected \<4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
Group Type
ACTIVE_COMPARATOR
Lyophilized Microbiota
Intervention Type
BIOLOGICAL
Lyophilized Microbiota will be delivered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Frozen Microbiota
Frozen Microbiota will be delivered via enema route.
Intervention Type
BIOLOGICAL
Lyophilized Microbiota
Lyophilized Microbiota will be delivered orally.
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female subjects 18 years of age or older
* Sexually active female subjects of child-bearing potential must agree to use an effective method of birth control during the treatment and follow-up period
* Required to sign an informed consent form
* Subject"s attending physician agrees to provide care following FMT
* Able to follow study procedures and follow-ups.
* Diagnosed by medical history of ≥ 3 RCDAD bouts in outpatients or ≥ 2 bouts of RCDAD in an inpatient with ≥ 2 positive fecal tests for C. difficile toxin
* Received at least one course of adequate antibiotic therapy for CDAD (≥ 10 days of vancomycin, metronidazole or fidaxomicin) after the subjects last bout of CDAD
* Sexually active female subjects of child-bearing potential must agree to use an effective method of birth control during the treatment and follow-up period
* Required to sign an informed consent form
* Subject"s attending physician agrees to provide care following FMT
* Able to follow study procedures and follow-ups.
* Diagnosed by medical history of ≥ 3 RCDAD bouts in outpatients or ≥ 2 bouts of RCDAD in an inpatient with ≥ 2 positive fecal tests for C. difficile toxin
* Received at least one course of adequate antibiotic therapy for CDAD (≥ 10 days of vancomycin, metronidazole or fidaxomicin) after the subjects last bout of CDAD
Exclusion Criteria
* Subjects with known neutropenia with absolute neutrophil count \<0.5 x 109/L
* Evidence of toxic megacolon, fulminant colitis, gastrointestinal perforation, ileus, abdominal distension, lack of bowel sounds, fever, or hypotension
* Known peripheral white blood cell count \> 15.0 x 109/L or temperature \> 38.0 °C
* Diarrhea due to definable non-CDAD pathogen
* Post total colectomy or presence of a colostomy
* Unable to tolerate FMT via enema for any reason
* Requiring systemic non-C. difficile antibiotic therapy at the time of FMT
* Actively taking Saccharomyces boulardii or other probiotic at the time of FMT
* Need for continuing use of oral vancomycin, oral or IV metronidazole, fidaxomicin, rifaximin or nitazoxanide at the time of FMT
* Severe underlying disease such that the patient is not expected to survive for one or more years or unstable medical condition requiring daily change in treatments
* Evidence of toxic megacolon, fulminant colitis, gastrointestinal perforation, ileus, abdominal distension, lack of bowel sounds, fever, or hypotension
* Known peripheral white blood cell count \> 15.0 x 109/L or temperature \> 38.0 °C
* Diarrhea due to definable non-CDAD pathogen
* Post total colectomy or presence of a colostomy
* Unable to tolerate FMT via enema for any reason
* Requiring systemic non-C. difficile antibiotic therapy at the time of FMT
* Actively taking Saccharomyces boulardii or other probiotic at the time of FMT
* Need for continuing use of oral vancomycin, oral or IV metronidazole, fidaxomicin, rifaximin or nitazoxanide at the time of FMT
* Severe underlying disease such that the patient is not expected to survive for one or more years or unstable medical condition requiring daily change in treatments
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roderick MacDonald Research Fund at Baylor St. Luke's
UNKNOWN
Sponsor Role
collaborator
Kelsey Research Foundation
OTHER
Sponsor Role
collaborator
Texas Gulf Coast Digestive Diseases Center
UNKNOWN
Sponsor Role
collaborator
The University of Texas Health Science Center, Houston
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhi-Dong Jiang
associate professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Herbert l DuPont, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas School of Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Health Science Center at Housotn
Houston, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500. No abstract available.
Reference Type
BACKGROUND
Gravel D, Gardam M, Taylor G, Miller M, Simor A, McGeer A, Hutchinson J, Moore D, Kelly S, Mulvey M; Canadian Nosocomial Infection Surveillance Program. Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada. Am J Infect Control. 2009 Feb;37(1):9-14. doi: 10.1016/j.ajic.2008.07.012.
Reference Type
BACKGROUND
Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008 Feb 1;197(3):435-8. doi: 10.1086/525047.
Reference Type
BACKGROUND
Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989 May 27;1(8648):1156-60. doi: 10.1016/s0140-6736(89)92749-9.
Reference Type
BACKGROUND
Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010 May-Jun;44(5):354-60. doi: 10.1097/MCG.0b013e3181c87e02.
Reference Type
BACKGROUND
Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010 Sep;44(8):562-6. doi: 10.1097/MCG.0b013e3181dac035.
Reference Type
BACKGROUND
Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010 May;8(5):471-3. doi: 10.1016/j.cgh.2010.01.007. Epub 2010 Feb 1.
Reference Type
BACKGROUND
Dupont HL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23; quiz e73. doi: 10.1016/j.cgh.2013.03.016. Epub 2013 Mar 28.
Reference Type
BACKGROUND
Jiang ZD, Hoang LN, Lasco TM, Garey KW, Dupont HL. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 Apr;56(7):1059-60. doi: 10.1093/cid/cis1025. Epub 2012 Dec 7. No abstract available.
Reference Type
BACKGROUND
Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS One. 2018 Nov 2;13(11):e0205064. doi: 10.1371/journal.pone.0205064. eCollection 2018.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSC-SPH-14-0020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff
NCT02254811
COMPLETED
PHASE2/PHASE3
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
NCT01704937
COMPLETED
PHASE1
Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
NCT01914731
COMPLETED
PHASE1
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
NCT02255305
TERMINATED
PHASE2
Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
NCT02801656
WITHDRAWN
PHASE3
Freeze-dried, Capsulized FMT for RCDI
NCT02399618
UNKNOWN
PHASE1
Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)
NCT01842347
WITHDRAWN
NA
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
NCT03712722
UNKNOWN
Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum
NCT02343328
TERMINATED
PHASE1
Fecal Microbiota Transplant
NCT04090346
COMPLETED
PHASE4
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
NCT03834038
COMPLETED
NA
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea
NCT00304876
COMPLETED
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
NCT04885946
UNKNOWN
NA
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
NCT03427229
COMPLETED
PHASE2
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
NCT01972334
COMPLETED
PHASE2
FMT in Uncomplicated Diverticulitis
NCT05373784
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection
NCT02394275
TERMINATED
PHASE2
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)
NCT03298048
TERMINATED
PHASE2
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
NCT04280471
WITHDRAWN
PHASE1
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
NCT01942447
UNKNOWN
NA
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
NCT03617445
TERMINATED
PHASE2
Fecal Microbiome Transplant
NCT02636517
ENROLLING_BY_INVITATION
PHASE1
Mucosal Versus Fecal Microbiota in FMT
NCT02133651
COMPLETED
Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection
NCT02148601
COMPLETED
PHASE2
Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
NCT04968951
TERMINATED
EARLY_PHASE1